Table 1.

Antibodies targeting Aβ.

Generic name	Primary Aβ target	CAA binding	ARIA-E rate	Clinical efficacy
Aducanumab	Fibrils/plaques	High	35%14	Yes/No14
Bapineuzumab	All forms	High	26.7%15	No15
Crenezumab	All forms	No	0.3%29	No54
Donanemab	Pyroglutamated Aβ, fibrils/plaques	Low/medium	24%16	Yes35
Gantenerumab	Fibrils/plaques	High	25%26,27	No28
Lecanemab	Protofibrils	Low	12.6%17	Yes17
Solanezumab	Monomers	No	0%31,32	No31,32